Comparing Astellas Pharma (OTCMKTS:ALPMY) & Evotec (NASDAQ:EVO)

Evotec (NASDAQ:EVO) and Astellas Pharma (OTCMKTS:ALPMY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Institutional & Insider Ownership

5.8% of Evotec shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Evotec and Astellas Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$862.40 million	0.96	-$212.18 million	N/A	N/A
Astellas Pharma	$12.56 billion	2.27	$334.93 million	$1.19	13.22

Astellas Pharma has higher revenue and earnings than Evotec.

Profitability

This table compares Evotec and Astellas Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	-21.24%	-18.20%	-8.58%
Astellas Pharma	15.63%	23.62%	10.96%

Analyst Ratings

This is a breakdown of current ratings for Evotec and Astellas Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1	1	3	0	2.40
Astellas Pharma	0	4	0	0	2.00

Evotec currently has a consensus price target of $7.00, indicating a potential upside of 199.15%. Given Evotec’s stronger consensus rating and higher probable upside, equities analysts clearly believe Evotec is more favorable than Astellas Pharma.

Risk & Volatility

Evotec has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Summary

Astellas Pharma beats Evotec on 6 of the 11 factors compared between the two stocks.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.